Phase Ib, Open-label, Multi-center Study of the Combination of Pertuzumab and Erlotinib in Patients With Locally Advanced or Metastatic (Stage IIIb/IV) NSCLC After Failure of at Least One Prior Chemotherapy Regimen.
Phase of Trial: Phase I
Latest Information Update: 22 Oct 2015
At a glance
- Drugs Erlotinib (Primary) ; Pertuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 20 Jun 2009 Status changed from active, no longer recruiting to completed as reported by Roche.
- 16 Jul 2008 Status changed from recruiting to in progress, from Roche record.
- 19 Aug 2007 Status changed from suspended to recruiting.